Aaron S Kesselheim1, Katsiaryna Bykov2, Joshua J Gagne2, Shirley V Wang2, Niteesh K Choudhry2. 1. From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. akesselheim@partners.org. 2. From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: With more antiepileptic drugs (AED) becoming available in generic form, we estimated the risk of seizure-related events associated with refilling generic AEDs and the effect of switching between different manufacturers of the same generic drug. METHODS: We designed a population-based case-crossover study using the Medicaid Analytic eXtract and a US commercial health insurance database. We identified 83,001 generic AED users who experienced a seizure-related hospital admission or emergency room visit between 2000 and 2013 and assessed whether they received a refill of the same AED from the same manufacturer or a different manufacturer. Patients served as their own controls and conditional logistic regression was used to compare exposure to a refill during the hazard period, defined as days 2-36 preceding the seizure-related event, to exposure during the control period, defined as days 51-85 preceding the seizure-related event. RESULTS: Generic AED refilling was associated with an 8% increase in the odds of seizure-related events (odds ratio [OR] 1.08; 95% confidence interval [CI] 1.06-1.11). The OR following a switch to a different manufacturer of the same AED was 1.09 (95% CI 1.03-1.15); however, after adjusting for the process of refilling, there was no association between switching and seizure-related hospital visits (OR 1.00; 95% CI 0.94-1.07). CONCLUSIONS: Among patients on a generic AED, refilling the same AED was associated with an elevated risk of seizure-related event; however, there was no additional risk from switching during that refill to a different manufacturer. Generic AEDs available to US patients, with Food and Drug Administration-validated bioequivalence, appear to be safe clinical choices.
OBJECTIVE: With more antiepileptic drugs (AED) becoming available in generic form, we estimated the risk of seizure-related events associated with refilling generic AEDs and the effect of switching between different manufacturers of the same generic drug. METHODS: We designed a population-based case-crossover study using the Medicaid Analytic eXtract and a US commercial health insurance database. We identified 83,001 generic AED users who experienced a seizure-related hospital admission or emergency room visit between 2000 and 2013 and assessed whether they received a refill of the same AED from the same manufacturer or a different manufacturer. Patients served as their own controls and conditional logistic regression was used to compare exposure to a refill during the hazard period, defined as days 2-36 preceding the seizure-related event, to exposure during the control period, defined as days 51-85 preceding the seizure-related event. RESULTS: Generic AED refilling was associated with an 8% increase in the odds of seizure-related events (odds ratio [OR] 1.08; 95% confidence interval [CI] 1.06-1.11). The OR following a switch to a different manufacturer of the same AED was 1.09 (95% CI 1.03-1.15); however, after adjusting for the process of refilling, there was no association between switching and seizure-related hospital visits (OR 1.00; 95% CI 0.94-1.07). CONCLUSIONS: Among patients on a generic AED, refilling the same AED was associated with an elevated risk of seizure-related event; however, there was no additional risk from switching during that refill to a different manufacturer. Generic AEDs available to US patients, with Food and Drug Administration-validated bioequivalence, appear to be safe clinical choices.
Authors: Barbara M Davit; Patrick E Nwakama; Gary J Buehler; Dale P Conner; Sam H Haidar; Devvrat T Patel; Yongsheng Yang; Lawrence X Yu; Janet Woodcock Journal: Ann Pharmacother Date: 2009-09-23 Impact factor: 3.154
Authors: Aaron S Kesselheim; Katsiaryna Bykov; Jerry Avorn; Angela Tong; Michael Doherty; Niteesh K Choudhry Journal: Ann Intern Med Date: 2014-07-15 Impact factor: 25.391
Authors: Aaron S Kesselheim; Alexander S Misono; William H Shrank; Jeremy A Greene; Michael Doherty; Jerry Avorn; Niteesh K Choudhry Journal: JAMA Intern Med Date: 2013-02-11 Impact factor: 21.873
Authors: Tricia Y Ting; Wenlei Jiang; Robert Lionberger; Jessica Wong; Jace W Jones; Maureen A Kane; Allan Krumholz; Robert Temple; James E Polli Journal: Epilepsia Date: 2015-07-23 Impact factor: 5.864
Authors: Olga S Matlin; Steven M Kymes; Alice Averbukh; Niteesh K Choudhry; Troyen A Brennan; Andred Bunton; Timothy A Ducharme; Peter D Simmons; William H Shrank Journal: Am J Manag Care Date: 2015-11 Impact factor: 2.229
Authors: Joshua J Gagne; Niteesh K Choudhry; Aaron S Kesselheim; Jennifer M Polinski; David Hutchins; Olga S Matlin; Troyen A Brennan; Jerry Avorn; William H Shrank Journal: Ann Intern Med Date: 2014-09-16 Impact factor: 25.391
Authors: M S Duh; P E Paradis; D Latrémouille-Viau; P E Greenberg; S P Lee; M B Durkin; G J Wan; M F T Rupnow; J LeLorier Journal: Neurology Date: 2009-06-16 Impact factor: 9.910
Authors: Joshua J Gagne; Jennifer R Popovic; Michael Nguyen; Sukhminder K Sandhu; Patty Greene; Rima Izem; Wenlei Jiang; Zhong Wang; Yueqin Zhao; Andrew B Petrone; Anita K Wagner; Sarah K Dutcher Journal: Drug Saf Date: 2018-12 Impact factor: 5.606
Authors: Ameet Sarpatwari; Joshua J Gagne; Zhigang Lu; Eric G Campbell; Wendy J Carman; Cheryl L Enger; Sarah K Dutcher; Wenlei Jiang; Aaron S Kesselheim Journal: J Gen Intern Med Date: 2019-01-10 Impact factor: 5.128
Authors: Samuel Waller Terman; Chun C Lin; Wesley T Kerr; Lindsey B DeLott; Brian C Callaghan; James F Burke Journal: Neurology Date: 2022-06-15 Impact factor: 11.800
Authors: Chana A Sacks; Victor L Van de Wiele; Lisa A Fulchino; Lajja Patel; Aaron S Kesselheim; Ameet Sarpatwari Journal: JAMA Intern Med Date: 2021-01-01 Impact factor: 21.873